Unregistered Sales of Equity Securities

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Holdings Corp," but the filing text identifies the registrant as Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2015 (Event Date); Signed December 4, 2015
Event: Unregistered Sales of Equity Securities (Item 3.02) and Regulation FD Disclosure (Item 7.01) related to the acquisition of assets from Equipois, LLC.

Key Financial Metrics and Transaction Details

The filing details an asset purchase agreement rather than standard periodic financial results. Key transaction metrics include:

  • Acquired Assets: Mechanical balance and support arms technologies, including rights to zeroG® and X-Ar® products, patents, trademarks, and product designs from Equipois, LLC.
  • Initial Consideration: 781,250 shares of Company Common Stock (Closing Shares).
  • Supply Earn-Out Payment: Up to $500,000 in additional shares payable by December 31, 2016, contingent on the Supply Agreement status.
  • Annual Earn-Out Payments: Between $125,000 and $375,000 in shares per year for 2016, 2017, and 2018, based on product sales performance.
  • Final Earn-Out Payment: Calculated based on a multiple (7.5x) of specified revenue percentages if the Reseller Agreement is terminated without cause.
  • Buyout Payment Options:
    • Company election: Total consideration not less than $2.5 million (if elected before Dec 1, 2016) or $3.0 million (if elected between Dec 1, 2016, and Nov 30, 2017).
    • Equipois election: Total consideration not less than $1.75 million (if elected before Dec 1, 2016) or $1.875 million (if elected between Dec 1, 2016, and Nov 30, 2017).

Liquidity and Debt: The filing text does not provide specific values for the Company's current cash flow, total debt, or liquidity position. The transaction is structured primarily as an equity issuance.

Material Changes and Agreements

The primary material change is the expansion of the Company's technology portfolio through the acquisition of Equipois assets. Key contractual arrangements include:

  • Supply Agreement: Equipois will supply Products to Ekso Bionics during a post-closing transition period.
  • Reseller Agreement: Equipois may purchase and resell Products to certain current customers for a three-year term.
  • Liability Assumption: The Company and Ekso Bionics assumed rights and obligations under certain IP license agreements but did not assume any other obligations of Equipois.

Guidance, Risks, and Contingencies

Share Issuance Mechanics: The number of shares for earn-out payments is determined by dividing the payment amount by a specific stock price formula (Volume-Weighted Average Price or a Minimum Price of $1.00-$1.28).

Lock-Up Provisions:

  • Closing Shares are subject to a phased lock-up: 50% sellable June 1, 2016; 75% sellable June 2, 2016; 100% sellable December 1, 2016.
  • Shares issued for Buyout or Final Earn-Out payments are subject to a similar one-year phased lock-up.
  • Resales are subject to volume limitations (max 5% of average daily trading volume).

Risks and Forward-Looking Statements: The filing includes standard forward-looking statement disclaimers. Identified risks include:

  • Inability to obtain adequate financing.
  • Lengthy product development timelines and resource requirements.
  • Failure to achieve market acceptance or effective marketing.
  • Adverse clinical study results.
  • Failure to obtain or maintain patent protection and regulatory approvals.
  • Increased competition and lack of product diversification.

Investor Verification Checklist

  • Verify the exact number of shares issued for the initial 781,250 Closing Shares and their impact on current dilution.
  • Monitor the status of the Supply and Reseller Agreements to determine if the $500,000 Supply Earn-Out Payment is triggered.
  • Track product sales figures for 2016-2018 to estimate potential Annual Earn-Out Payments ($125k-$375k/year).
  • Review the Company's cash position to assess its ability to fund operations alongside potential future equity issuances.
  • Confirm regulatory approval status for the acquired zeroG® and X-Ar® products.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.